Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Goodwill (2023 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Goodwill for 3 consecutive years, with $48.2 million as the latest value for Q4 2025.

  • Quarterly Goodwill changed 0.0% to $48.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.2 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $48.2 million for FY2025, 0.0% changed from the prior year.
  • Goodwill for Q4 2025 was $48.2 million at Cartesian Therapeutics, roughly flat from $48.2 million in the prior quarter.
  • The five-year high for Goodwill was $48.2 million in Q4 2023, with the low at $48.2 million in Q4 2023.
  • Average Goodwill over 3 years is $48.2 million, with a median of $48.2 million recorded in 2023.
  • Peak annual rise in Goodwill hit 0.0% in 2024, while the deepest fall reached 0.0% in 2024.
  • Over 3 years, Goodwill stood at $48.2 million in 2023, then changed by 0.0% to $48.2 million in 2024, then changed by 0.0% to $48.2 million in 2025.
  • According to Business Quant data, Goodwill over the past three periods came in at $48.2 million, $48.2 million, and $48.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.